SyntheticMR's software solution SyMRI receives regulatory approval in Japan
STOCKHOLM, Sept. 3, 2020 /PRNewswire/ -- "We are proud to bring our SyMRI software to the Japanese market" says Ulrik Harrysson, CEO, SyntheticMR. "We have an established customer base in Japan currently using the product for research. Now we are excited to be able to offer SyMRI for clinical use on the Japanese market. We know there are many healthcare providers that are looking forward to utilize our technology to speed up their current workflow and add additional information to aid in diagnosis."
SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-6-minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice.
During the BIO 2024 International Convention, the Department of Health ? Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Opus Genetics, a patient-first, clinical-stage gene...
Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human (FIH) Phase I/II clinical trial with PFL-002/VERT-002 for solid...
On May 10, 2024, nursing students from Unitek College volunteered at the 25th Northern Nevada Nurses of Achievement Awards Dinner where Unitek was a distinguished sponsor. This prestigious event celebrated the outstanding contributions of nurses in...
International medical imaging IT and cybersecurity company Sectra (STO: SECT-B) reports that all operating areas are growing, and the Group's sales for the fourth quarter surpassed earlier record-breaking levels. Cloud recurring revenue (CRR) is...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks...
